334 related articles for article (PubMed ID: 37195491)
1. Baricitinib for the Treatment of Alopecia Areata.
Freitas E; Guttman-Yassky E; Torres T
Drugs; 2023 Jun; 83(9):761-770. PubMed ID: 37195491
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
[TBL] [Abstract][Full Text] [Related]
4. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B; Ohyama M; Kwon O; Zlotogorski A; Ko J; Mesinkovska NA; Hordinsky M; Dutronc Y; Wu WS; McCollam J; Chiasserini C; Yu G; Stanley S; Holzwarth K; DeLozier AM; Sinclair R;
N Engl J Med; 2022 May; 386(18):1687-1699. PubMed ID: 35334197
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
[TBL] [Abstract][Full Text] [Related]
6. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
[TBL] [Abstract][Full Text] [Related]
7. Review of Baricitinib in the Treatment of Alopecia Areata.
Singh R; Driscoll MS
J Drugs Dermatol; 2023 Sep; 22(9):935-940. PubMed ID: 37683061
[TBL] [Abstract][Full Text] [Related]
8. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
Lensing M; Jabbari A
Front Immunol; 2022; 13():955035. PubMed ID: 36110853
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2.
Taylor S; Korman NJ; Tsai TF; Shimomura Y; Feely M; Dutronc Y; Wu WS; Somani N; Tosti A
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3181-3191. PubMed ID: 37740856
[TBL] [Abstract][Full Text] [Related]
11. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib: A Review in Severe Alopecia Areata.
Fung S; Shirley M
Am J Clin Dermatol; 2023 Jul; 24(4):661-668. PubMed ID: 37326792
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
[TBL] [Abstract][Full Text] [Related]
14. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
15. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
Jabbari A; Dai Z; Xing L; Cerise JE; Ramot Y; Berkun Y; Sanchez GA; Goldbach-Mansky R; Christiano AM; Clynes R; Zlotogorski A
EBioMedicine; 2015 Apr; 2(4):351-5. PubMed ID: 26137574
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
Ramírez-Marín HA; Tosti A
Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
[TBL] [Abstract][Full Text] [Related]
17. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.
King B; Shapiro J; Ohyama M; Egeberg A; Piraccini BM; Craiglow B; Sinclair R; Chen YF; Wu WS; Ding Y; Somani N; Dutronc Y
Br J Dermatol; 2023 Nov; 189(6):666-673. PubMed ID: 37708254
[TBL] [Abstract][Full Text] [Related]
18. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
Ismail FF; Sinclair R
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
[No Abstract] [Full Text] [Related]
19. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
20. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
Stefanis AJ
Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
